Carret Asset Management LLC Acquires New Stake in Bionano Genomics, Inc. (NASDAQ:BNGO)

Carret Asset Management LLC acquired a new stake in shares of Bionano Genomics, Inc. (NASDAQ:BNGO) in the fourth quarter, HoldingsChannel reports. The firm acquired 18,000 shares of the company’s stock, valued at approximately $34,000.

Separately, Dark Forest Capital Management LP increased its position in Bionano Genomics by 1,024.2% during the 3rd quarter. Dark Forest Capital Management LP now owns 141,747 shares of the company’s stock valued at $429,000 after buying an additional 129,138 shares in the last quarter. 11.35% of the stock is owned by hedge funds and other institutional investors.

Bionano Genomics Price Performance

Shares of NASDAQ:BNGO traded down $0.01 during midday trading on Thursday, hitting $0.75. The company had a trading volume of 470,151 shares, compared to its average volume of 1,631,048. Bionano Genomics, Inc. has a twelve month low of $0.71 and a twelve month high of $8.20. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.40 and a quick ratio of 1.17. The stock has a market cap of $41.02 million, a price-to-earnings ratio of -0.11 and a beta of 2.33. The business’s 50-day simple moving average is $1.06 and its 200-day simple moving average is $1.38.

Bionano Genomics (NASDAQ:BNGO) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.96) EPS for the quarter. Bionano Genomics had a negative return on equity of 103.68% and a negative net margin of 643.74%. The firm had revenue of $10.72 million for the quarter. On average, research analysts predict that Bionano Genomics, Inc. will post -2.35 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Scotiabank dropped their price target on Bionano Genomics from $7.00 to $6.00 and set a “sector outperform” rating on the stock in a research note on Thursday, March 7th.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.